Survival with triple-negative BC (TNBC; minimal/nil expression of the estrogen receptor, progesterone receptor, and HER2), which accounts for 10-20% of all BC (9, 10), is 10, 20, and 30% lower at stages 2, 3, and 4, respectively, compared to non-TNBC (11). This evidence concerns the gene PGR and breast cancer.